These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
219 related items for PubMed ID: 16979735
1. Clinical model of lifetime cost of treating bladder cancer and associated complications. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS. Urology; 2006 Sep; 68(3):549-53. PubMed ID: 16979735 [Abstract] [Full Text] [Related]
2. Clinical model of cost of bladder cancer in the elderly. Cooksley CD, Avritscher EB, Grossman HB, Sabichi AL, Dinney CP, Pettaway C, Elting LS. Urology; 2008 Mar; 71(3):519-25. PubMed ID: 18342201 [Abstract] [Full Text] [Related]
3. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D. Cancer; 2006 May 01; 106(9):1875-82. PubMed ID: 16572409 [Abstract] [Full Text] [Related]
4. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis. Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M, Oshiro Y, Hokama S, Sugaya K, Ogawa Y. Urology; 2007 Feb 01; 69(2):275-9. PubMed ID: 17320663 [Abstract] [Full Text] [Related]
5. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Etzioni R, Ramsey SD, Berry K, Brown M. Health Econ; 2001 Apr 01; 10(3):245-56. PubMed ID: 11288190 [Abstract] [Full Text] [Related]
7. Patient time costs associated with cancer care. Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, Warren JL. J Natl Cancer Inst; 2007 Jan 03; 99(1):14-23. PubMed ID: 17202109 [Abstract] [Full Text] [Related]
9. Economic implications of growth hormone use in patients with short bowel syndrome. Migliaccio-Walle K, Caro JJ, Möller J. Curr Med Res Opin; 2006 Oct 03; 22(10):2055-63. PubMed ID: 17022865 [Abstract] [Full Text] [Related]
10. Economic consequences of an implanted neuroprosthesis for bladder and bowel management. Creasey GH, Dahlberg JE. Arch Phys Med Rehabil; 2001 Nov 03; 82(11):1520-5. PubMed ID: 11689970 [Abstract] [Full Text] [Related]
12. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Bennett CL, Calhoun EA. Oncologist; 2007 Apr 03; 12(4):478-83. PubMed ID: 17470690 [Abstract] [Full Text] [Related]
13. Productivity losses attributable to untreated chlamydial infection and associated pelvic inflammatory disease in reproductive-aged women. Blandford JM, Gift TL. Sex Transm Dis; 2006 Oct 03; 33(10 Suppl):S117-21. PubMed ID: 17003678 [Abstract] [Full Text] [Related]
16. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. Huse DM, Song X, Ozminkowski RJ, Maguire J, Williams SA, Borok GM, McDonough K. Clin Ther; 2006 Sep 03; 28(9):1425-42. PubMed ID: 17062315 [Abstract] [Full Text] [Related]